Download This Paper
Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
Optimizing HIV Retesting During Pregnancy and Postpartum in Four Countries: A Cost-Effectiveness Analysis
64 Pages Posted: 26 Jun 2020
More...Abstract
Background: HIV retesting during late pregnancy and breastfeeding can help detect new maternal infections and prevent mother-to-child HIV transmission (MTCT), but the optimal timing and cost-effectiveness of maternal retesting is uncertain.
Methods: We constructed Markov models to assess the health and economic impact of maternal HIV retesting, following initial testing in pregnancy, on MTCT in four countries: South Africa and Kenya (high/intermediate HIV prevalence), and Colombia and Ukraine (low HIV prevalence). We evaluated six scenarios with varying retesting frequencies from the second antenatal care visit (ANC) through nine months postpartum. We compared strategies using incremental cost-effectiveness ratios (ICERs) over a 20-year time horizon using country-specific thresholds.
Findings: Maternal retesting once at second ANC with catch-up testing through six weeks postpartum was cost-effective in Kenya (ICER=$166 per DALY averted) and South Africa (ICER=$289 per DALY averted). This strategy prevented 19% (Kenya) and 12% (South Africa) of infant HIV infections. Adding one or two additional retests postpartum provided smaller benefits (1-2% additional infections averted versus one retest). Adding three retests during the postpartum period averted additional infections (1-3% additional infections averted versus one retest) but ICERs ($7,639 and in Kenya and $11,985 in South Africa) greatly exceeded the cost-effectiveness thresholds. In Colombia and Ukraine, all retesting strategies exceeded the cost-effectiveness threshold and prevented few infant infections (up to 31 and 5 infections, respectively).
Interpretation: In high HIV burden settings, HIV retesting once at second ANC, with subsequent intervention, is the most cost-effective strategy for preventing infant HIV infections. In these settings, two HIV retests postpartum marginally reduced MTCT and was less costly than adding three retests. Retesting in Colombia and Ukraine was not cost-effective at any time point due to very low HIV prevalence and limited breastfeeding.
Funding: This study was funded by WHO #201742717, WHO #018/CDS/HIV/004, WHO #2018/865307-0, USAID GHA‐G‐ 00‐09‐00003, and the Bill and Melinda Gates Foundation OPP1177903, and supported by NIH/NIAID P30‐ AI027757, NIH/NIAID K01 AI116298 (ALD), NIH/NIMH K01 MH115789 (MS) and NIH/NIEHS T32 ES015459-09 (JM).
Declaration of Interests: The authors declare no competing interests.
Ethics Approval Statement: Missing.
Keywords: HIV; pregnancy; postpartum; mother-to-child HIV transmission; prevention of mother-to-child HIV transmission; cost effectiveness; maternal and child health
Suggested Citation: Suggested Citation